menu
    • menu
    [{"orgOrder":0,"company":"Treos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"PolyPEPI1018","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Luminous Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Financing","leadProduct":"PolyPEPI-1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Luminous Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Luminous Ventures"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Mayo Clinic | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PolyPEPI1018 CRC Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Mayo Clinic | F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Mayo Clinic | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Mayo Clinic | University of Pisa | LabCorp | PPD | ImmunXperts","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"PolyPEPI1018 CRC Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Mayo Clinic | University of Pisa | LabCorp | PPD | ImmunXperts","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Mayo Clinic | University of Pisa | LabCorp | PPD | ImmunXperts"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI-SCoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Montanide ISA 51VG","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Treos Bio

    Menu

    Treos Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI1018,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Shanghai Junshi Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TREOS Partners with Charité Berlin and Junshi to Launch Pivotal Phase II Trial

                            Details : The collaboration aims to initiate OBERTO-202, a potentially registration-enabling Phase II evaluating PolyPEPI1018 in combination with toripalimab, Junshi Biosciences' PD-1 inhibitor, in MSS CRC.

                            Product Name : PolyPEPI1018

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 27, 2025

                            Lead Product(s) : PolyPEPI1018,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Shanghai Junshi Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI1018 CRC Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Mayo Clinic | F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

                            Details : PolyPEPI1018 CRC Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 17, 2022

                            Lead Product(s) : PolyPEPI1018 CRC Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Mayo Clinic | F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI-1018

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Luminous Ventures

                            Deal Size : $14.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Treos Bio Announces $14 Million Convertible Loan Note Financing

                            Details : Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 31, 2021

                            Lead Product(s) : PolyPEPI-1018

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Luminous Ventures

                            Deal Size : $14.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI-SCoV-2 Peptide Vaccine,Montanide ISA 51VG

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Res...

                            Details : PolyPEPI-SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant was safe in two mouse models and elicited highly specific, TH1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 19, 2020

                            Lead Product(s) : PolyPEPI-SCoV-2 Peptide Vaccine,Montanide ISA 51VG

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI-SCoV-2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine

                            Details : Treos Bio has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 15, 2020

                            Lead Product(s) : PolyPEPI-SCoV-2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Treos Bio

                            United Kingdom arrow
                            BOS Manchester
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI1018

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Pos...

                            Details : Treos plans to conduct a randomized Phase II study of PolyPEPI1018 in maintenance therapy setting for first-line treatment of MSS mCRC, as well as a Phase I/II study in late-stage patients as an add-on to third-line therapy.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 29, 2020

                            Lead Product(s) : PolyPEPI1018

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed

                            Treos Bio

                            United Kingdom arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PolyPEPI1018 CRC Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Mayo Clinic | University of Pisa | LabCorp | PPD | ImmunXperts

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)

                            Details : PolyPEPI1018 CRC Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 05, 2018

                            Lead Product(s) : PolyPEPI1018 CRC Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Mayo Clinic | University of Pisa | LabCorp | PPD | ImmunXperts

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth